Free Trial
NASDAQ:BMEA

Biomea Fusion Q4 2024 Earnings Results & Report

Biomea Fusion logo
$0.60 +0.05 (+9.69%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomea Fusion beat analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.81 versus the -$1.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Biomea Fusion EPS Results

Actual EPS
-$0.81
Consensus EPS
-$1.00
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Q4 2024 Earnings FAQ

Biomea Fusion (NASDAQ:BMEA) reported earnings of -$0.81 per share for Q4 2024, beating the consensus estimate of -$1.00. The report was announced on Monday, March 31, 2025.

Biomea Fusion Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on Tuesday
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets.

Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes. BMF-500 is another investigational program intended to target menin-related biology.

Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion conducts research and clinical development activities aimed at addressing diseases with significant unmet medical needs. The company is led by Thomas Butler, who serves as co-founder, chairman and chief executive officer. Its programs are investigational and have not been approved for commercial use by regulatory authorities.

View Biomea Fusion Profile